Evolent Health Class A (EVH) closed at $4.25 on October 29, 2026, down 1.8% from the previous close, on volume of 1,232,823 shares (30-day average 2,000,360).
Data as of October 29, 2026.
No headlines found.
Evolent To Release Third Quarter 2026 Financial Results on Thursday, November 5, 2026
PRNewswire (Fri, 9-Oct 4:30 PM ET)
TransPerfect Selected by Evolent for Enterprise-Wide Telephonic Interpretation
Globe Newswire (Mon, 21-Sep 10:00 AM ET)
Evolent Announces Second Quarter 2026 Results
PRNewswire (Thu, 6-Aug 7:01 AM ET)
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.
Evolent Health Class A trades on the NYSE stock market under the symbol EVH.
As of October 29, 2026, EVH stock price declined to $4.25 with 1,232,823 million shares trading.
EVH has a beta of 2.18, meaning it tends to be more sensitive to market movements. EVH has a correlation of 0.08 to the broad based SPY ETF.
EVH has a market cap of $480.50 million. This is considered a Small Cap stock.
Last quarter Evolent Health Class A reported $653 million in Revenue and $.02 earnings per share. This beat revenue expectation by $51 million and exceeded earnings estimates by $.05.
In the last 3 years, EVH traded as high as $35.00 and as low as $2.10.
The top ETF exchange traded funds that EVH belongs to (by Net Assets): IWM, VTI, FNDA, VXF, JSMD.
EVH has underperformed the market in the last year with a price return of -42.6% while the SPY ETF gained +13.1%. However, in the short term, EVH had mixed performance relative to the market. It has outperformed in the last 3 months, returning +13.6% vs +4.1% return in SPY. But in the last 2 weeks, EVH shares have been beat by the market, returning -10.1% compared to an SPY return of 0.0%.
EVH support price is $4.12 and resistance is $4.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EVH shares will trade within this expected range on the day.
